A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

Part of paid clinical trials in Plantation, Florida.

Sponsor
UCB Biopharma SRL
Study ID
NCT07720375
Phase
PHASE2
Status
Recruiting

Conditions

  • Non-cystic Fibrosis Bronchiectasis

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Galvokimig — BIOLOGICAL
    Drug: Galvokimig Pharmaceutical form: Solution for injection
  • Placebo — BIOLOGICAL
    Drug: Placebo Pharmaceutical form: Solution for injection

Study Details

The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)

Key Dates

First listed
Jul 22, 2026
Start date
Aug 5, 2026
Status verified
Aug 2026
Primary completion
Feb 28, 2029
Completion
Apr 26, 2029

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Galvokimig Dose 1 Arm
    Participants randomly assigned to this arm will receive Galvokimig Dose 1
  • Experimental: Galvokimig Dose 2 Arm
    Participants randomly assigned to this arm will receive Galvokimig Dose 2
  • Experimental: Galvokimig Dose 3 Arm
    Participants randomly assigned to this arm will receive Galvokimig Dose 3
  • Placebo Comparator: Placebo Arm
    Participants randomly assigned to this arm will receive a matching Placebo.

Primary Outcome Measure

Time from intervention assignment to first moderate or severe pulmonary exacerbation [ Time Frame: Up to Week 52 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Ncfb01 50005PlantationFlorida33324-7006-
Ncfb01 50004DuBoisPennsylvania15801-
Ncfb01 50001McKinneyTexas75069-

Find similar trials in Plantation, FL

Related Studies